Maximizing impact: the power of early HPV vaccination for long-term protection―lessons from a systematic review and meta-regression analysis
HPV16/18-AS04 vaccine provides long-term protection against cervical premalignant lesions and cervical cancer in both controlled and real-world settings, particularly when administered at younger ages. The evidence urges policymakers and the community to ensure HPV vaccination begins at the youngest recommended ages.
Authors
- Emmanuel ARIS
- Andrea Callegaro (ORCID: https://orcid.org/0000-0003-4805-5118)
- Bernd Benninghoff (ORCID: https://orcid.org/0000-0003-1264-7074)
- Volker Vetter (ORCID: https://orcid.org/0000-0002-8414-1657)
- Adoración Navarro-Torné (ORCID: https://orcid.org/0000-0002-1644-2415)
- Huifeng Yun (ORCID: https://orcid.org/0000-0002-0158-1797)
Institutions
- GlaxoSmithKline (Belgium) (BE)
- Infectious Disease Consultants (US)
- GlaxoSmithKline (United States) (US)
- Anna Needs Neuroblastoma Answers (US)
- GlaxoSmithKline (Switzerland) (CH)
- Diagnostics for the Real World (United States) (US)
Publication Details
- Journal
- Journal of Public Health
- Published
- 2026-01-30
- DOI
- https://doi.org/10.1093/pubmed/fdag002
- Primary Topic
- Cervical Cancer and HPV Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00